Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)

Condition(s) targeted: Male and Female Subjects, Greater Than 60 Years of Age With Non-M3 AML

Intervention: Eltrombopag (Drug)

Phase: Phase 1/Phase 2

Status: Recruiting

Sponsored by: Abramson Cancer Center of the University of Pennsylvania

Official(s) and/or principal investigator(s):
Noelle Frey, MD, Principal Investigator, Affiliation: Abramson Cancer Center of the University of Pennsylvania

Overall contact:
Amanda Gordon, RN, Phone: (215)-663-6392, Email: amanda.gordon@uphs.upenn.edu

This is a phase I/II open label study being conducted to evaluate the overall safety and initial effectiveness of an investigational drug, Eltrombopag in patients who are 60 years of age and older and who have Acute Myelogenous Leukemia (AML). Eltrombopag is an investigational drug, which means it has not been approved by the U. S. Food and Drug Administration (FDA) for use in this type of disease. Approximately 35 people will be enrolled on this study at the University of Pennsylvania

Official title: A Phase I/II Study of Eltrombopag in Elderly Patients With AML

Study design: Primary Purpose: Treatment

Primary outcome:

Phase I Portion

Phase II portion:

Secondary outcome:

Overall response rate (Phase I and Phase II)

Survival, Response and Progression

Detailed description: Primary Objectives (Phase I Portion): 1). To determine the safety and tolerability of eltrombopag in elderly subjects with AML 2). To determine the maximally tolerated initial starting dose of eltrombopag for elderly subjects with AML Primary Objectives (Phase II portion): 1). To better define the safety and tolerability of eltrombopag in elderly patients with AML at the maximally tolerated starting dose Page 9 of 18 determined in Phase I portion of study. 2). To determine the incidence of peripheral platelet count improvement (using baseline and response parameters as defined below) for subjects with disease related thrombocytopenia. Secondary Objectives (Phase I and II): 1). To preliminarily determine the efficacy (using AML response criteria as defined below) of eltrombopag in elderly subjects with AML.

2). To perform ex-vivo analyses using subject AML samples and stock eltrombopag to 1) assess leukemic proliferative capacity and 2) investigate potential eltrombopag induced cytoxic mechanisms for leukemic cell death. 3). To perform pharmacodynamic assessments of drug activity in leukemic cells using subject samples collected at various time points before and during drug exposure. 4). To preliminarily correlate pharmacodynamic findings with clinical response.

Minimum age: 60 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- A diagnosis of non-M3 AML which is either: a). Relapsed after standard chemotherapy

or transplant;

- Newly diagnosed in a patient who is not an appropriate or willing candidate for

standard induction chemotherapy - Age equal to or greater than 60 - Platelet count

less than 75 - ECOG performance status of 0-2

- Life expectancy of at least 4 weeks

- Must be able to consume oral medication

- Must have recovered from toxic effects of prior chemotherapy

- Patients must be able to sign consent and be willing and able to comply with

scheduled visits, treatment plan and laboratory testing.

- For Phase I portion only: Subject must be of non-East Asian (Japanese, Chinese,

Taiwanese or Korean) descent.

- For Phase II portion subject can be either East Asian or non-East Asian descent.

Exclusion Criteria:

- Cytotoxic chemotherapy (including azacitadine or decitabine) within the past 28 days

other than hydroxyurea

- Active participation in any other investigational treatment study for AML.

- Known HIV or Hepatitis C

- ECOG performance status greater than 2

- Uncontrolled intercurrent illness including, but not limited to: uncontrolled ongoing

infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

- Previous therapy with romiplostim or any other TPO-R agonist

Amanda Gordon, RN, Phone: (215)-663-6392, Email: amanda.gordon@uphs.upenn.edu

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States; Recruiting
Amanda Gordon, RN, Phone: 215-663-6392, Email: amanda.gordon@uphs.upenn.edu

Starting date: April 2010
Last updated: September 22, 2010